https://scholars.lib.ntu.edu.tw/handle/123456789/596943
標題: | Vinorelbine plus 24-hour infusion of high-dose 5-fluorouracil and leucovorin as effective palliative chemotherapy for breast cancer patients with acute disseminated intravascular coagulation | 作者: | PO-HAN LIN YEN-SHEN LU CHING-HUNG LIN DWANG-YING CHANG CHIUN-SHENG HUANG ANN-LII CHENG KUN-HUEI YEH |
公開日期: | 2010 | 卷: | 30 | 期: | 7 | 起(迄)頁: | 3087-3091 | 來源出版物: | Anticancer Research | 摘要: | Background: Cancer-related acute disseminated intravascular coagulation (DIC) is uncommon, but it is a severe complication resulting in a very dismal prognosis. Choosing the appropriate chemotherapy agents to treat the underlying cancer and stop the acute DIC process effectively, while avoiding chemotherapy-induced myelosuppression which may contribute to bleeding-related mortality, is difficult. Acute DlC in breast cancer is a rare condition and is not well studied. Therefore, we designed this study to determine the clinical characteristics and effective treatment for breast cancer patients with acute DlC. Patients and Methods: From March 1996 to November 2008, patients with histologically proven breast cancer who presented with acute DIC at National Taiwan University Hospital were retrospectively analyzed. Results: Sixteen patients were included in the study. Thirteen patients with breast cancer-related acute DIC were treated with various kinds of chemotherapy, one with tamoxifen, and two with supportive care only. Four patients responded to treatment; three of the responders received vinorelbine with high-dose 5-fluorouracil and leucovorin (HDFL), the other received vinorelbine with cisplatin. The median survival of the responders and non-responders was 13 months and 0.5 month (p<0.001). There were no grade 3 or 4 hematologic or non-hematologic toxicities in the patients receiving vinorelbine-HDFL. Conclusion: Vinorelbine plus HDFL is considered a safe and effective palliative treatment of choice for breast cancer patients with acute DIC. Further prospective study is warranted. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-77955803972&partnerID=40&md5=b983caab0d19b9408c8ffdb6cb4de17e https://scholars.lib.ntu.edu.tw/handle/123456789/596943 |
ISSN: | 0250-7005 | SDG/關鍵字: | cisplatin; D dimer; docetaxel; fluorouracil; folinic acid; navelbine; adult; aged; article; blood clotting disorder; breast cancer; cancer combination chemotherapy; cancer control; cancer palliative therapy; cancer patient; cancer survival; cancer therapy; clinical article; clinical feature; disseminated intravascular clotting; drug effect; drug megadose; drug safety; female; histology; human; neutropenia; partial thromboplastin time; priority journal; prospective study; prothrombin time; thrombocytopenia; treatment duration; treatment response; Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disseminated Intravascular Coagulation; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Middle Aged; Retrospective Studies; Vinblastine |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。